Phase 2 N=15 Treatment

Memantine Augmentation in Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

Bottom Line

View on ClinicalTrials.gov: NCT00264238 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2017

Primary outcome: Primary: Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks) — 23.8; 30; 13.0; 28.8 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Memantine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Stanford University
Primary completion: Jun 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) From Baseline to End of Treatment (12 Weeks)	23.8; 30; 13.0; 28.8	—
SECONDARY Mean Change in Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to End of Treatment (12 Weeks)	11.8; 14.9; 5.0; 14.6	—

Summary

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

Eligibility Criteria

Inclusion Criteria

at least 18 years of age
suffering from OCD
Y-BOCS score of 18 or greater
taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria

diagnosed with a mental disorder other than OCD
taking tiagabine or pregabalin
having had a previous trial of memantine
receiving therapy for OCD
substance abuse in the last 6 months
personality disorders sufficiently severe to interfere with study participation

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00264238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.